TCRX (TScan Therapeutics) Current Accrued Expense : $6.14 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is TScan Therapeutics Current Accrued Expense?

TScan Therapeutics's Current Accrued Expense for the quarter that ended in Sep. 2024 was $6.14 Mil.

TScan Therapeutics's quarterly Current Accrued Expense increased from Mar. 2024 ($6.30 Mil) to Jun. 2024 ($7.04 Mil) but then declined from Jun. 2024 ($7.04 Mil) to Sep. 2024 ($6.14 Mil).

TScan Therapeutics's annual Current Accrued Expense declined from Dec. 2021 ($2.91 Mil) to Dec. 2022 ($2.05 Mil) but then increased from Dec. 2022 ($2.05 Mil) to Dec. 2023 ($4.81 Mil).

TScan Therapeutics Current Accrued Expense Historical Data

The historical data trend for TScan Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TScan Therapeutics Current Accrued Expense Chart

TScan Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Current Accrued Expense

0.07

0.83

2.91

2.05

4.81

TScan Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Current Accrued Expense	Get a 7-Day Free Trial															4.83	4.81	6.30	7.04	6.14

TScan Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

TScan Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of TScan Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

TScan Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TScan Therapeutics Inc (NAS:TCRX) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.tscan.com

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Executives

Lynx1 Capital Management Lp	10 percent owner	151 CALLE DE SAN FRANCISCO, SUITE 200 PMB 1237, SAN JUAN PR 00901-1607
Barbara Klencke	director	C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Zoran Zdraveski	officer: Chief Legal Officer	C/O MAGENTA THERAPEUTICS, 50 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Timothy J Barberich	director	40 ELM ST, CONCORD MA 01752
Leiden Dworak	officer: Chief Accounting Officer	C/O TSCAN THERAPEUTICS, INC., 880 WINTER STREET, WALTHAM MA 02451
Weston Nichols	10 percent owner	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Brian M. Silver	officer: Chief Financial Officer	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Debora Barton	officer: Chief Medical Officer	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
David P Southwell	director, officer: Chief Executive Officer	C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014